Kimberly L Blackwell

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi Are all aromatase inhibitors alike?
    Kimberly L Blackwell
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center, P O Box 3893, Durham, NC 27710, USA
    Breast Cancer Res Treat 112:35-43. 2008
  2. ncbi Hyperthermia for locally advanced breast cancer
    Timothy M Zagar
    Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Int J Hyperthermia 26:618-24. 2010
  3. ncbi Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence: a review of the randomised data
    Timothy M Zagar
    Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Int J Hyperthermia 26:612-7. 2010
  4. ncbi Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease
    Christina I Herold
    Duke Comprehensive Cancer Center, Durham, NC 27710, USA
    Clin Breast Cancer 8:50-64. 2008
  5. ncbi Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer
    Kimberly L Blackwell
    Duke University Medical Center, Durham, NC 27701, USA
    J Clin Oncol 28:1124-30. 2010
  6. ncbi DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: a pilot study
    Oana I Craciunescu
    Duke University Medical Center, Durham, NC 27710, USA
    Int J Hyperthermia 25:405-15. 2009
  7. ncbi Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer
    Neil L Spector
    Duke Translational Research Oncology Program, Duke University Hospital, Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 27:5838-47. 2009
  8. ncbi Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2
    Michael A Morse
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Box 3233, Durham, NC 27710, USA
    J Transl Med 5:42. 2007
  9. ncbi Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression
    Carey K Anders
    Duke University Medical Center, Box 3841, 3829 Duke South, Red Zone, Durham, NC 27710, USA
    J Clin Oncol 26:3324-30. 2008
  10. ncbi Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu+ tumors
    Matthew E Hardee
    Department of Pathology, Duke University Medical Center, Durham, NC 22710, USA
    Cancer Chemother Pharmacol 63:219-28. 2009

Collaborators

Detail Information

Publications17

  1. ncbi Are all aromatase inhibitors alike?
    Kimberly L Blackwell
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center, P O Box 3893, Durham, NC 27710, USA
    Breast Cancer Res Treat 112:35-43. 2008
    ..No safety differences between the AIs have yet been identified. This article explores the pharmacologic and clinical differences between the AIs, based on data from clinical and preclinical studies...
  2. ncbi Hyperthermia for locally advanced breast cancer
    Timothy M Zagar
    Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Int J Hyperthermia 26:618-24. 2010
    ..The goal of this review is to highlight important research utilising HT in patients with LABC as well as to suggest future directions for its use...
  3. ncbi Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence: a review of the randomised data
    Timothy M Zagar
    Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Int J Hyperthermia 26:612-7. 2010
    ..In this review article, we will highlight the important prospective data that has been published regarding the combined use of hyperthermia and radiation...
  4. ncbi Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease
    Christina I Herold
    Duke Comprehensive Cancer Center, Durham, NC 27710, USA
    Clin Breast Cancer 8:50-64. 2008
    ..Ongoing trials include head-to-head comparisons between the AIs in early-stage breast cancer; the results of these trials are eagerly anticipated and should further optimize the use of AIs...
  5. ncbi Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer
    Kimberly L Blackwell
    Duke University Medical Center, Durham, NC 27701, USA
    J Clin Oncol 28:1124-30. 2010
    ..EGF104900 compared the activity of lapatinib alone or in combination with trastuzumab in patients with ErbB2-positive, trastuzumab-refractory metastatic breast cancer (MBC)...
  6. ncbi DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: a pilot study
    Oana I Craciunescu
    Duke University Medical Center, Durham, NC 27710, USA
    Int J Hyperthermia 25:405-15. 2009
    ..The MPTS was extracted from pre-treatment MRI parameters, so independent of the combined therapy used...
  7. ncbi Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer
    Neil L Spector
    Duke Translational Research Oncology Program, Duke University Hospital, Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 27:5838-47. 2009
    ..The mechanisms of action of trastuzumab have not been fully elucidated, and data available to date are reviewed here. The impact of the mechanisms of action on clinical benefit also is discussed...
  8. ncbi Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2
    Michael A Morse
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Box 3233, Durham, NC 27710, USA
    J Transl Med 5:42. 2007
    ..We proposed to address these concerns by using cancer vaccines to stimulate HER2 intracellular domain (ICD)-specific T cell and antibody responses...
  9. ncbi Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression
    Carey K Anders
    Duke University Medical Center, Box 3841, 3829 Duke South, Red Zone, Durham, NC 27710, USA
    J Clin Oncol 26:3324-30. 2008
    ..Breast cancer arising in young women is correlated with inferior survival and higher incidence of negative clinicopathologic features. The biology driving this aggressive disease has yet to be defined...
  10. ncbi Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu+ tumors
    Matthew E Hardee
    Department of Pathology, Duke University Medical Center, Durham, NC 22710, USA
    Cancer Chemother Pharmacol 63:219-28. 2009
    ..The growth factor receptor, Her2/neu, is overexpressed in 25-30% of breast tumors. Tumors that are Her2(+) may have an altered state of oxygenation, relative to Her2(-) tumors, due to differences in tumor growth rate and angiogenesis...
  11. ncbi Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes
    Michael L Gatza
    Duke Institute for Genome Sciences and Policy, Duke University Medical Center, CIEMAS Building, 101Science Dr, Durham, NC 27708, USA
    Breast Cancer Res 13:R62. 2011
    ..Although the importance of these non-genetic factors is well recognized, it is not clear how to integrate these factors within the genetic framework of cancer as the next logical step in understanding tumor heterogeneity...
  12. ncbi Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors
    Wenle Xia
    Duke Comprehensive Cancer Research Center, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
    Mol Cancer Ther 10:1367-74. 2011
    ..Elucidating the function of nuclear, truncated forms of ErbB2, and developing therapeutic strategies to block their expression and/or activation may enhance the clinical efficacy of ErbB2 TKIs...
  13. ncbi New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response
    Erika Hamilton
    Department of Medicine Medical Oncology, Duke University Medical Center, Durham, NC, USA
    Cancer Invest 29:533-41. 2011
    ..These new data provide growing insight into a potential mechanism of action for some of the anticancer activity demonstrated by zoledronic acid in breast cancer clinical trials...
  14. ncbi Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases
    Barbara Adamo
    Department of Medicine, Division of Hematology Oncology, CB 7305, University of North Carolina, Chapel Hill, NC 27599, USA
    Breast Cancer Res 13:R125. 2011
    ..Secondary analyses included PI3K pathway activation status and associations with time to distant recurrence (TTDR) and time to BCBMs. Similar analyses were also conducted among the subset of patients with triple-negative BCBMs...
  15. ncbi Comparative genome-wide screening identifies a conserved doxorubicin repair network that is diploid specific in Saccharomyces cerevisiae
    Tammy J Westmoreland
    Department of Surgical Sciences, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 4:e5830. 2009
    ....
  16. ncbi The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer
    Christina I Herold
    Duke Comprehensive Cancer Center, Durham, North Carolina 27710, USA
    Breast 17:S15-24. 2008
    ..Possible differences in efficacy may be related to differences in potency. Two ongoing trials directly comparing two AIs - the Femara versus Anastrozole Clinical Evaluation and MA.27 - may provide further information...
  17. ncbi Safety of bevacizumab in patients with metastatic breast cancer
    Erika P Hamilton
    Duke University Medical Center, Durham, NC 27710, USA
    Oncology 80:314-25. 2011
    ..Current adverse event management strategies, based on guidelines and experience from these trials, are outlined...